Jaffee E - Search Results

1

Nanoparticle interactions with immune cells dominate tumor retention and induce T cell-mediated tumor suppression in models of breast cancer.

Korangath P, Barnett JD, Sharma A, Henderson ET, Stewart J, Yu SH, Kandala SK, Yang CT, Caserto JS, Hedayati M, Armstrong TD, Jaffee E, Gruettner C, Zhou XC, Fu W, Hu C, Sukumar S, Simons BW, Ivkov R. Korangath P, et al. Among authors: jaffee e. Sci Adv. 2020 Mar 25;6(13):eaay1601. doi: 10.1126/sciadv.aay1601. eCollection 2020 Mar. Sci Adv. 2020. PMID: 32232146 Free PMC article.

2

Compromised HOXA5 function can limit p53 expression in human breast tumours.

Raman V, Martensen SA, Reisman D, Evron E, Odenwald WF, Jaffee E, Marks J, Sukumar S. Raman V, et al. Among authors: jaffee e. Nature. 2000 Jun 22;405(6789):974-8. doi: 10.1038/35016125. Nature. 2000. PMID: 10879542

3

Cytokine modified tumor vaccines.

Armstrong TD, Jaffee EM. Armstrong TD, et al. Surg Oncol Clin N Am. 2002 Jul;11(3):681-96. doi: 10.1016/s1055-3207(02)00020-0. Surg Oncol Clin N Am. 2002. PMID: 12487062 Review.

4

Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients.

Thomas AM, Santarsiero LM, Lutz ER, Armstrong TD, Chen YC, Huang LQ, Laheru DA, Goggins M, Hruban RH, Jaffee EM. Thomas AM, et al. J Exp Med. 2004 Aug 2;200(3):297-306. doi: 10.1084/jem.20031435. J Exp Med. 2004. PMID: 15289501 Free PMC article.

5

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response.

Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JP, Bieler JG, Emens LA, Reilly RT, Jaffee EM. Ercolini AM, et al. J Exp Med. 2005 May 16;201(10):1591-602. doi: 10.1084/jem.20042167. Epub 2005 May 9. J Exp Med. 2005. PMID: 15883172 Free PMC article.

6

Allergies and the risk of pancreatic cancer: a meta-analysis with review of epidemiology and biological mechanisms.

Gandini S, Lowenfels AB, Jaffee EM, Armstrong TD, Maisonneuve P. Gandini S, et al. Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1908-16. doi: 10.1158/1055-9965.EPI-05-0119. Cancer Epidemiol Biomarkers Prev. 2005. PMID: 16103436 Review.

7

OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen.

Murata S, Ladle BH, Kim PS, Lutz ER, Wolpoe ME, Ivie SE, Smith HM, Armstrong TD, Emens LA, Jaffee EM, Reilly RT. Murata S, et al. Among authors: jaffee em. J Immunol. 2006 Jan 15;176(2):974-83. doi: 10.4049/jimmunol.176.2.974. J Immunol. 2006. PMID: 16393983

8

Ductal access for prevention and therapy of mammary tumors.

Murata S, Kominsky SL, Vali M, Zhang Z, Garrett-Mayer E, Korz D, Huso D, Baker SD, Barber J, Jaffee E, Reilly RT, Sukumar S. Murata S, et al. Among authors: jaffee e. Cancer Res. 2006 Jan 15;66(2):638-45. doi: 10.1158/0008-5472.CAN-05-4329. Cancer Res. 2006. PMID: 16423990

9

Mechanisms of immune evasion by tumors.

Drake CG, Jaffee E, Pardoll DM. Drake CG, et al. Among authors: jaffee e. Adv Immunol. 2006;90:51-81. doi: 10.1016/S0065-2776(06)90002-9. Adv Immunol. 2006. PMID: 16730261 Review.

10

A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism.

Manning EA, Ullman JG, Leatherman JM, Asquith JM, Hansen TR, Armstrong TD, Hicklin DJ, Jaffee EM, Emens LA. Manning EA, et al. Clin Cancer Res. 2007 Jul 1;13(13):3951-9. doi: 10.1158/1078-0432.CCR-07-0374. Clin Cancer Res. 2007. PMID: 17606729

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

334 results

Search Page